author-photo

Lina Setti

Novartis

7

Papers

107

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

2019 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (14)
Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

2017 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (25)
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors

2015 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (10)
Discovery of Potent and Selective RSK Inhibitors as Biological Probes.

2015 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (35)